Dyax - Advancing Novel Biotherapeutics

Dyax.com: Research

Publications

Publications

  1. Chen J, Tetrault J, Zhang Y, Wasserman A, Conley G, Dileo M, Haimes E, Nixon AE, Ley A.  The distinctive separation attributes of mixed-mode resins and their application in monoclonal antibody downstream purification process.  J Chromatogr A.  2010;1217(2):216-24.
  2. Cicardi M, Levy RJ, McNeil DL, Li HH, Sheffer AL, Campion M, Horn PT, Pullman WE.  Ecallantide for the treatment of acute attacks in hereditary angioedema.  N Engl J Med 2010;363(6):523-31.
  3. Dransfield DT, Cohen EH, Chang Q, Sparrow LG, Bentley JD, Dolezal O, Xiao X, Peat TS, Newman J, Pilling PA, Phan T, Priebe I, Brierley GV, Kastrapeli N, Kopacz K, Martik D, Wassaf D, Rank D, Conley G, Huang Y, Adams TE, Cosgrove L.  A human monoclonal antibody against insulin-like growth factor-II blocks the growth of human hepatocellular carcinoma cell lines in vitro and in vivo.  Mol Cancer Ther.  2010;9(6):1809-19.
  4. Levy RJ, Lumry WR, McNeil DL, Li HH, Campion M, Horn PT, Pullman WE.  EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema.  Ann Allergy Asthma Immunol 2010;104(6):523-9.
  5. Stolz LE, Horn PT.  Ecallantide: A plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema.  Drugs Today (Barc) 2010;46(8):547-55.
  6. Wilson DA, Bork K, Shea EP, Rentz AM, Blaustein MB, Pullman WE.  Economic costs associated with acute attacks and long-term management of hereditary angioedema.  Ann Allergy Asthma Immunol 2010;104(4):314-20.
  7. Devy L, Huang L, Naa L, Yanamandra N, Pieters H, Frans N, Chang E, Tao Q, Vanhove M, Lejeune A, van Gool R, Sexton DJ, Kuang G, Rank D, Hogan S, Pazmany C, Ma YL, Schoonbroodt S, Nixon AE, Ladner RC, Hoet R, Henderikx P, Tenhoor C, Rabbani SA, Valentino ML, Wood CR, Dransfield DT.  Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis.  Cancer Res.  2009;69(4):1517-26.
  8. Vernon MK, Rentz AM, Wyrwich KW, White MV, Grienenberger A.  Psychometric validation of two patient-reported outcome measures to assess symptom severity and changes in symptoms in hereditary angioedema.  Qual Life Res 2009;18(7):929-39.
  9. Sexton DJ, Chen T, Martik D, Kuzmic P, Kuang G, Chen J, Nixon AE, Zuraw BL, Forteza RM, Abraham WM, Wood CR.  Specific inhibition of tissue kallikrein 1 with a human monoclonal antibody reveals a potential role in airway diseases.  Biochem J 2009;422(2):383-92.
  10. Schoonbroodt S, Steukers M, Viswanathan M, Frans N, Timmermans M, Wehnert A, Nguyen M, Ladner RC, Hoet RM.  Engineering antibody heavy chain CDR3 to create a phage display Fab library rich in antibodies that bind charged carbohydrates.  J Immunol 2008;181(9):6213-21.
  11. Buckler DR, Park A, Viswanathan M, Hoet RM, Ladner RC.  Screening isolates from antibody phage-display libraries.  Drug Discov Today 2008;13(7-8):318-24.
  12. Devy L, Rabbani SA, Stochl M, Ruskowski M, Mackie I, Naa L, Toews M, van Gool R, Chen J, Ley A, Ladner RC, Dransfield DT, Henderikx P.  PEGylated DX-1000: pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor.  Neoplasia 2007;9(11):927-37.
  13. Schneider L, Lumry W, Vegh A, Williams AH, Schmalbach T.  Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor.  J Allergy Clin Immunol 2007;120(2):416-22.
  14. Levy JH, O'Donnell PS.  The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema.  Expert Opin Investig Drugs 2006;15(9):1077-90.
  15. Nixon AE, Wood CR.  Engineered protein inhibitors of proteases.  Curr Opin Drug Discov Devel 2006;9(2):261-8.
  16. Wassaf D, Kuang G, Kopacz K, Wu QL, Nguyen Q, Toews M, Cosic J, Jacques J, Wiltshire S, Lambert J, Pazmany CC, Hogan S, Ladner RC, Nixon AE, Sexton DJ.  High-throughput affinity ranking of antibodies using surface plasmon resonance microarrays.  Anal Biochem 2006;351(2):241-53.
  17. Steukers M, Schaus JM, van Gool R, Hoyoux A, Richalet P, Sexton DJ, Nixon AE, Vanhove M.  Rapid kinetic-based screening of human Fab fragments.  J Immunol Methods 2006;310(1-2):126-35.
  18. Hoet RM, Cohen EH, Kent RB, Rookey K, Schoonbroodt S, Hogan S, Rem L, Frans N, Daukandt M, Pieters H, van Hegelsom R, Neer NC, Nastri HG, Rondon IJ, Leeds JA, Hufton SE, Huang L, Kashin I, Devlin M, Kuang G, Steukers M, Viswanathan M, Nixon AE, Sexton DJ, Hoogenboom HR, Ladner RC.  Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity.  Nat Biotechnol 2005;23(3):344-8.
  19. Jostock T, Vanhove M, Brepoels E, Van Gool R, Daukandt M, Wehnert A, Van Hegelsom R, Dransfield D, Sexton D, Devlin M, Ley A, Hoogenboom H, Mullberg J.  Rapid generation of functional human IgG antibodies derived from Fab-on-phage display libraries.  J Immunol Methods 2004;289(1-2):65-80.
  20. Williams A, Baird LG.  DX-88 and HAE: a developmental perspective.  Transfus Apher Sci 2003;29(3):255-8.

Please contact us with questions about our publications.

You are now leaving Dyax.com.
The web site you are about to visit is neither owned nor controlled by Dyax Corp. Dyax is not responsible for the content, products or services on this site.

Do you wish to continue?